Now, the center has two “well” beds and six “sick” beds, as well as two waiting areas that separate sick patients from well patients. The space further separates sick patients and well patients by allowing two separate exits so well patients are not exposed to areas sick patients have been.
Vaccine manufacturing and regulatory expert and business development and strategy leader bring further expertise as company advances RSV vaccine candidate into Phase 2 and scales production of an intranasal COVID-19 vaccine candidate for clinical trials
Meissa Vaccines (“Meissa”), a biotechnology company developing vaccines to prevent viral respiratory infections, announced today the appointments of William (Bill) Daly, J.D., MBA, as Chief Business Officer and Keith H. Wells, Ph.D., as Chief Manufacturing Officer. Mr. Daly brings more than 30 years of broad experience in the biotech and pharma industry, covering business development, operations, finance, and strategy. Dr. Wells has been involved in the development of more than 90 vaccines and biopharmaceutical products, and most recently advised the Biomedical Advanced Research and Development Authority (BARDA) on the advanced development, licensure, and acquisition of medical countermeasures.
“The expansion of the leadership team comes at a pivotal time for Meissa as we are advancing one